GlycoMimetics registers $86m IPO for orphan disease programs
This article was originally published in Scrip
Now that Pfizer has taken on Phase III development for GlycoMimetics's lead drug candidate GMI-1070 for sickle cell disease, and since it had just $10.8m in cash as of 30 June, the Gaithersburg, Maryland-based company has registered for an initial public offering to raise up to $86.25m for early clinical and preclinical programs.
You may also be interested in...
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug?